Cases reported "Adrenocortical Carcinoma"

Filter by keywords:



Filtering documents. Please wait...

1/2. Expression of endothelin-1 by adrenocortical carcinoma: a new target for anti-cancer therapy?

    adrenocortical carcinoma is a rare neoplasm with poor prognosis. endothelin-1 (ET-1) has been implicated in carcinogenesis, but has never been studied in this neoplasm. A 76-year-old woman with Cushing's syndrome due adrenocortical carcinoma was operated on and the tumour removed was studied by immunohistochemistry for ET-1. Patient history illustrates the poor prognosis of this cancer that became metastatic after one year. Immunohistochemical studies disclosed a strong expression of ET-1 by adrenocortical carcinoma cells. As shown in other cancers, ET-1 expression by adrenocortical carcinoma may suggest a pathogenic role of ET-1 in tumorigenesis that possibly could be countered by ET-1 receptor antagonists. These agents could open new therapeutic perspectives to treat a carcinoma known to have a poor prognosis.
- - - - - - - - - -
ranking = 1
keywords = tumorigenesis
(Clic here for more details about this article)

2/2. Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci.

    Presented is a rare case of nonfamilial, hormonally nonfunctional adrenocortical carcinoma with synchronous bilateral adrenal involvement. We investigated adrenal and metastatic tumors for loss of heterozygosity affecting four genetic loci containing the tumor suppressor genes p53, RB, DCC, and APC, using polymerase chain reaction and restriction fragment length polymorphism assay. Allelic losses at the p53 and RB loci were detected in all tumor samples, suggesting that the p53 and RB genes are involved in the tumorigenesis of adrenocortical carcinoma.
- - - - - - - - - -
ranking = 1
keywords = tumorigenesis
(Clic here for more details about this article)


Leave a message about 'Adrenocortical Carcinoma'


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.